Evoke Pharma Statistics
Total Valuation
Evoke Pharma has a market cap or net worth of $10.48 million. The enterprise value is $4.14 million.
Important Dates
The next estimated earnings date is Thursday, March 13, 2025, after market close.
| Earnings Date | Mar 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evoke Pharma has 2.07 million shares outstanding. The number of shares has increased by 429.66% in one year.
| Current Share Class | 1.49M |
| Shares Outstanding | 2.07M |
| Shares Change (YoY) | +429.66% |
| Shares Change (QoQ) | +5.40% |
| Owned by Insiders (%) | 3.32% |
| Owned by Institutions (%) | 3.72% |
| Float | 1.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| Forward PS | 3.33 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 1.14.
| Current Ratio | 1.44 |
| Quick Ratio | 1.37 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.76 |
Financial Efficiency
Return on equity (ROE) is -349.91% and return on invested capital (ROIC) is -54.51%.
| Return on Equity (ROE) | -349.91% |
| Return on Assets (ROA) | -33.50% |
| Return on Invested Capital (ROIC) | -54.51% |
| Return on Capital Employed (ROCE) | -134.45% |
| Revenue Per Employee | $2.15M |
| Profits Per Employee | -$1.54M |
| Employee Count | 4 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 0.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.76% in the last 52 weeks. The beta is 0.15, so Evoke Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | -38.76% |
| 50-Day Moving Average | 4.69 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 55.10 |
| Average Volume (20 Days) | 8,462 |
Short Selling Information
The latest short interest is 41,708, so 2.02% of the outstanding shares have been sold short.
| Short Interest | 41,708 |
| Short Previous Month | 38,714 |
| Short % of Shares Out | 2.02% |
| Short % of Float | 3.29% |
| Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, Evoke Pharma had revenue of $8.62 million and -$6.15 million in losses. Loss per share was -$4.17.
| Revenue | 8.62M |
| Gross Profit | 8.32M |
| Operating Income | -5.90M |
| Pretax Income | -7.13M |
| Net Income | -6.15M |
| EBITDA | n/a |
| EBIT | -5.90M |
| Loss Per Share | -$4.17 |
Full Income StatementBalance Sheet
The company has $11.34 million in cash and $5.00 million in debt, giving a net cash position of $6.34 million or $3.07 per share.
| Cash & Cash Equivalents | 11.34M |
| Total Debt | 5.00M |
| Net Cash | 6.34M |
| Net Cash Per Share | $3.07 |
| Equity (Book Value) | 4.39M |
| Book Value Per Share | 2.97 |
| Working Capital | 4.27M |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.32M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.32M |
| FCF Per Share | -$2.58 |
Full Cash Flow StatementMargins
Gross margin is 96.55%, with operating and profit margins of -68.45% and -71.33%.
| Gross Margin | 96.55% |
| Operating Margin | -68.45% |
| Pretax Margin | -71.33% |
| Profit Margin | -71.33% |
| EBITDA Margin | n/a |
| EBIT Margin | -68.45% |
| FCF Margin | n/a |